Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Preclinical
Recipient : Inceptor Bio
Deal Size : Undisclosed
Deal Type : Collaboration
Details : Under the agreement, Inceptor will utilize Avectas' SOLUPORE® technology as an alternative to electroporation for engineering T cells with the goal to yield a healthier T cell product.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
December 10, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Recipient : Inceptor Bio
Deal Size : Undisclosed
Deal Type : Collaboration